+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
VEGF Inhibitors for Cancer Market - Global Forecast 2025-2030- Product Image
VEGF Inhibitors for Cancer Market - Global Forecast 2025-2030- Product Image
Sale

VEGF Inhibitors for Cancer Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6147637
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Comprehensive Introduction to the Evolutionary Importance of VEGF Inhibitors in Advancing Oncology Therapeutics and Improving Patient Outcomes

Vascular endothelial growth factor has emerged as a cornerstone in the battle against tumor angiogenesis. By disrupting the signals that drive new blood vessel formation, VEGF inhibitors have transformed the standard of care across multiple solid tumors. From their initial approval to subsequent expansions into combination regimens, these therapies have continually reshaped clinical expectations and extended patient survival.

Over time, advancements in antibody engineering and small molecule design have broadened the scope of VEGF-targeted interventions. Monoclonal antibodies and fusion proteins have demonstrated potent efficacy profiles, while tyrosine kinase inhibitors have introduced oral administration formats that improve patient convenience. This evolution reflects a deeper understanding of pharmacokinetics and tumor biology, underscoring the adaptive nature of oncological research.

As oncology moves toward precision medicine, VEGF inhibitors occupy a unique nexus between antiangiogenic strategies and immunomodulation. Future research is poised to integrate biomarker-driven patient selection, optimize dosing regimens, and explore novel combinations with immunotherapies. Consequently, these agents will remain central to therapeutic innovation and will continue to influence treatment algorithms worldwide.

Detailed Examination of Recent Transformative Shifts Shaping the VEGF Inhibitor Landscape and Their Impact on Oncology Treatment Strategies

In recent years, the VEGF inhibitor landscape has experienced transformative shifts driven by scientific breakthroughs and strategic collaborations. Precision oncology efforts have enabled the identification of predictive biomarkers, resulting in more targeted use of antiangiogenic agents. Meanwhile, the integration of immunotherapeutic regimens with VEGF inhibitors has yielded synergistic effects, offering durable responses in cancer types once deemed refractory.

Moreover, the rise of biosimilar monoclonal antibodies has intensified competition, reducing barriers to access and pressuring innovator pricing strategies. Concurrently, advances in formulation science have produced sustained-release and subcutaneous delivery systems, expanding the utility of these agents in outpatient settings. These developments highlight the industry’s commitment to enhancing patient adherence and quality of life.

Furthermore, real-world evidence initiatives and adaptive trial designs have accelerated regulatory pathways, allowing breakthrough therapies to reach clinicians more rapidly. In parallel, digital health platforms are being leveraged to monitor angiogenesis biomarkers and treatment response, enabling more agile adjustments to therapy. Collectively, these shifts underscore a dynamic environment where innovation, data-driven decision making, and patient centricity converge to reshape the future of VEGF inhibition.

Insightful Analysis of the Cumulative Effects of United States Tariffs Introduced in 2025 on the VEGF Inhibitor Market Dynamics

The introduction of United States tariffs on key pharmaceutical imports in 2025 has reverberated across supply chains for VEGF inhibitors. Many active pharmaceutical ingredients and excipients sourced from overseas now face elevated duties, which in turn translate into increased manufacturing costs. Consequently, some producers have accelerated plans for domestic API production or diversified their supplier base to mitigate exposure to these levies.

In response, companies have reevaluated pricing frameworks and engaged payers in negotiations to preserve formulary access. Simultaneously, strategic stockpiling and long-term purchase agreements emerged as tactical measures to stabilize inventories and manage cost volatility. These efforts have underscored the importance of supply chain resilience, prompting collaborations with contract manufacturing and development organizations to shore up capacity.

Despite these challenges, tariff-induced cost increases have also catalyzed innovation in process intensification and bioprocess optimization, as firms seek efficiencies to offset higher input costs. As a result, lean manufacturing practices and continuous processing have gained traction, offering both economic benefits and environmental sustainability improvements. Ultimately, the 2025 tariffs have prompted a comprehensive reassessment of operational models, fostering a more adaptable and cost-effective production ecosystem.

Key Segmentation Insights Unveiling How Indication, Molecule Type, Administration Route, End User and Product Type Shape Cancer Therapeutic Markets

Insight into how market segmentation influences strategic decision making in the VEGF inhibitor sector reveals a multifaceted picture. When examining use by indication, it becomes clear that therapies targeting colorectal cancer and lung cancer continue to dominate clinical focus, while emerging opportunities in hepatocellular carcinoma, ovarian cancer, and renal cell carcinoma are attracting significant development effort. This diversity in therapeutic application drives portfolio breadth and prioritization decisions across organizations.

Equally important is the distinction among molecule types. Fusion proteins such as aflibercept offer ligand-scavenging mechanisms, whereas monoclonal antibodies including bevacizumab and ramucirumab deliver targeted blockade of receptor activation. Tyrosine kinase inhibitors, represented by pazopanib, sorafenib, and sunitinib, introduce the flexibility of oral dosing and multiple kinase inhibition profiles. These varied molecular modalities complement one another, creating a balanced pipeline that addresses both systemic and localized angiogenic pathways.

Route of administration further differentiates patient experience, with intravenous infusions predominantly used in hospital settings and oral regimens enabling at-home administration. End users encompass ambulatory surgical centers, cancer research facilities, hospitals, and specialty clinics, each presenting unique operational dynamics and procurement channels. Finally, the distinction between branded and generic products shapes competitive intensity and access strategies. Together, these interconnected layers of segmentation inform product positioning, investment allocation, and lifecycle management within the VEGF inhibitor market.

Comprehensive Regional Insights Highlighting VEGF Inhibitor Market Trends Across the Americas, Europe Middle East Africa and Asia Pacific

Regional analysis of the VEGF inhibitor market underscores diverse growth trajectories and adoption patterns. In the Americas, robust research infrastructure and favorable reimbursement frameworks have accelerated the uptake of both novel therapeutics and biosimilars. Strong collaboration between academia and industry has further expanded clinical trial volumes, reinforcing North America’s position as a center of innovation.

In the Europe, Middle East and Africa region, regulatory harmonization initiatives and widening access programs have improved availability of VEGF inhibitors. Countries with established healthcare systems benefit from streamlined approval pathways, while emerging markets within this region present opportunities for tiered pricing models and public-private partnerships aimed at addressing unmet oncology needs.

Meanwhile, Asia-Pacific markets exhibit rapid pharmaceutical manufacturing expansion and growing oncology patient populations. Government investment in domestic biotech hubs and incentives for research partnerships are catalyzing local development of biosimilars and next-generation angiogenesis inhibitors. This dynamic landscape, characterized by both advanced and emerging economies, contributes to a complex ecosystem where demand growth is balanced by the need for value-based access solutions.

Key Companies Insights Revealing Strategic Initiatives, Collaborative Partnerships, and Competitive Positioning of Leading VEGF Inhibitor Developers in Oncology

Leading organizations continue to refine their VEGF inhibitor portfolios through strategic alliances, targeted acquisitions, and robust clinical pipelines. Roche’s flagship monoclonal antibody maintains a strong position in multiple indications, supported by numerous lifecycle extension studies and combination trials. Similarly, the collaboration between Regeneron and Bayer on aflibercept underscores the power of co-development agreements in accelerating global market reach.

Large pharmaceutical companies such as Pfizer and Bayer have leveraged tyrosine kinase inhibitors to capture oral oncology segments, investing in head-to-head trials and label expansions to differentiate products like pazopanib, sorafenib, and sunitinib. Smaller biotech entrants are increasingly focusing on specialized formulations, next-generation molecules with improved safety profiles, and digital companion diagnostics to carve out niche opportunities.

The competitive landscape also features aggressive biosimilar manufacturers that have reduced treatment costs and fostered wider adoption of VEGF-targeted therapies. Partnerships between generics producers and contract manufacturing organizations are enabling faster market entry. Overall, these strategic initiatives and collaborative frameworks illustrate a vibrant industry ecosystem committed to advancing antiangiogenic science.

Actionable Recommendations Empowering Industry Leaders to Optimize Efficacy, Accelerate Development, and Navigate Regulatory Complexities in VEGF Inhibitor Markets

To capitalize on evolving market dynamics, industry leaders should prioritize integrated supply chain strategies that incorporate local API production and diversified sourcing, thereby reducing tariff-related risks. Investing in continuous manufacturing technologies and lean process optimization will further mitigate cost pressures and enhance operational agility.

Simultaneously, fostering early collaborations with regulatory authorities can expedite approval of combination regimens and novel formulations. Engaging in real-world data initiatives and adaptive trial designs will build robust evidence packages that support differentiated value propositions to payers and clinicians. In parallel, deploying precision medicine approaches through biomarker-driven patient selection can optimize therapeutic outcomes and reinforce payer confidence in reimbursement.

Finally, aligning commercial models with regional access requirements-such as tiered pricing in emerging markets and outcome-based agreements in developed regions-will ensure sustainable growth. By embracing digital health platforms and virtual care pathways, companies can enhance patient adherence, capture longitudinal evidence, and strengthen competitive positioning in the rapidly evolving VEGF inhibitor arena.

Robust Research Methodology Outlining Data Collection, Analytical Approaches, and Validation Processes Underpinning VEGF Inhibitor Market Insights

Our research methodology integrates comprehensive secondary research with targeted primary engagements to deliver balanced and validated market insights. In the initial phase, extensive literature reviews, regulatory database analyses, and clinical trial registry examinations establish a factual baseline for industry trends and scientific advancements.

Subsequently, in-depth interviews with key opinion leaders, industry executives, and supply chain experts provide qualitative context and real-time perspectives. Data from company filings, patent landscapes, and competitive intelligence reports are triangulated to ensure accuracy and relevance. Analytical frameworks such as SWOT and Porter's Five Forces are applied to assess market drivers, challenges, and strategic imperatives.

Throughout the process, rigorous validation workshops are conducted to cross-verify findings and refine assumptions. This iterative approach ensures that our conclusions are not only grounded in empirical evidence but also resonate with on-the-ground realities experienced by stakeholders. By combining quantitative analysis with expert validation, the study delivers a holistic view of the VEGF inhibitor market.

Conclusive Synthesis Summarizing Critical Findings and Strategic Implications of VEGF Inhibitor Trends in Contemporary Oncology Practice

This study synthesizes the critical developments in VEGF inhibitor science, market structure, and strategic positioning to offer a cohesive narrative of current and future trends. By examining segmentation, regional dynamics, and competitive activities, key takeaways emerge that can inform decision-making across R&D, commercial, and policy domains.

Strategic collaborations and technological innovations continue to drive portfolio diversification and clinical expansion. Meanwhile, regulatory adaptations and supply chain realignments reflect an industry in flux, responding to external challenges while upholding patient access and quality standards. The interplay between branded and biosimilar avenues also highlights the dual imperative of innovation and affordability.

In conclusion, stakeholders equipped with these insights will be well positioned to navigate the complexities of the VEGF inhibitor ecosystem. Embracing data-driven strategies and agile operating models will be essential for capturing growth opportunities and delivering transformative outcomes for patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Colorectal Cancer
    • Hepatocellular Carcinoma
    • Lung Cancer
    • Ovarian Cancer
    • Renal Cell Carcinoma
  • Molecule Type
    • Fusion Proteins
    • Monoclonal Antibodies
      • Aflibercept
      • Bevacizumab
      • Ramucirumab
    • Small Molecules
    • Tyrosine Kinase Inhibitors
      • Pazopanib
      • Sorafenib
      • Sunitinib
  • Route Of Administration
    • Intravenous
    • Oral
  • End User
    • Ambulatory Surgical Centers
    • Cancer Research Facilities
    • Hospitals
    • Specialty Clinics
  • Product Type
    • Branded
    • Generic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd.
  • Exelixis, Inc.
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Ipsen S.A.
  • Eli Lilly and Company
  • Bayer AG
  • Novartis AG
  • Amgen Inc.
  • Merck KGaA

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in bispecific VEGF and PD-1 inhibitor combinations improving tumor response rates
5.2. Emerging oral small molecule VEGF inhibitors offering improved patient convenience and adherence
5.3. Development of biomarker-driven VEGF inhibitor therapies for personalized cancer treatment strategies
5.4. Rising investments in nanoparticle delivery systems to enhance VEGF inhibitor tumor penetration
5.5. Increasing regulatory approvals of next-generation VEGF inhibitors for multiple solid tumor indications
5.6. Collaborations between biotechs and academia driving novel VEGF inhibitor discovery platforms
5.7. Adoption of real-world evidence to assess long-term safety and efficacy of VEGF inhibitors in oncology
5.8. Integration of artificial intelligence in screening for VEGF inhibitor responsiveness in cancer patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. VEGF Inhibitors for Cancer Market, by Indication
8.1. Introduction
8.2. Colorectal Cancer
8.3. Hepatocellular Carcinoma
8.4. Lung Cancer
8.5. Ovarian Cancer
8.6. Renal Cell Carcinoma
9. VEGF Inhibitors for Cancer Market, by Molecule Type
9.1. Introduction
9.2. Fusion Proteins
9.3. Monoclonal Antibodies
9.3.1. Aflibercept
9.3.2. Bevacizumab
9.3.3. Ramucirumab
9.4. Small Molecules
9.5. Tyrosine Kinase Inhibitors
9.5.1. Pazopanib
9.5.2. Sorafenib
9.5.3. Sunitinib
10. VEGF Inhibitors for Cancer Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. VEGF Inhibitors for Cancer Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cancer Research Facilities
11.4. Hospitals
11.5. Specialty Clinics
12. VEGF Inhibitors for Cancer Market, by Product Type
12.1. Introduction
12.2. Branded
12.3. Generic
13. Americas VEGF Inhibitors for Cancer Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa VEGF Inhibitors for Cancer Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific VEGF Inhibitors for Cancer Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.2. Exelixis, Inc.
16.3.3. Eisai Co., Ltd.
16.3.4. Pfizer Inc.
16.3.5. Ipsen S.A.
16.3.6. Eli Lilly and Company
16.3.7. Bayer AG
16.3.8. Novartis AG
16.3.9. Amgen Inc.
16.3.10. Merck KGaA
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. VEGF INHIBITORS FOR CANCER MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. VEGF INHIBITORS FOR CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. VEGF INHIBITORS FOR CANCER MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. VEGF INHIBITORS FOR CANCER MARKET: RESEARCHAI
FIGURE 26. VEGF INHIBITORS FOR CANCER MARKET: RESEARCHSTATISTICS
FIGURE 27. VEGF INHIBITORS FOR CANCER MARKET: RESEARCHCONTACTS
FIGURE 28. VEGF INHIBITORS FOR CANCER MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VEGF INHIBITORS FOR CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY RAMUCIRUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY RAMUCIRUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PAZOPANIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PAZOPANIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SORAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SORAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SUNITINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SUNITINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY CANCER RESEARCH FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY CANCER RESEARCH FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 106. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 107. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. CANADA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 120. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 121. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 187. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 190. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 191. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 192. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 193. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 204. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 205. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 206. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 207. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 232. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 233. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 234. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 235. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. ITALY VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 246. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 247. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 248. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 249. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 250. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 251. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 256. SPAIN VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 298. SOUTH AFRICA VEGF INHIBITORS FOR CANCER MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 299. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 300. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 301. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 302. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 303. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 304. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 305. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 306. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 307. DENMARK VEGF INHIBITORS FOR CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this VEGF Inhibitors for Cancer Market report include:
  • F. Hoffmann-La Roche Ltd.
  • Exelixis, Inc.
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Ipsen S.A.
  • Eli Lilly and Company
  • Bayer AG
  • Novartis AG
  • Amgen Inc.
  • Merck KGaA

Related Topics

Related Reports

Anti-VEGF Therapy for Cancer Market - Global Forecast 2025-2030 - Product Image

Anti-VEGF Therapy for Cancer Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Monoclonal Antibody VEGF Inhibitors Market - Global Forecast 2025-2030 - Product Image

Monoclonal Antibody VEGF Inhibitors Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Vascular Endothelial Growth Factor A Inhibitors - Pipeline Insight, 2025 - Product Image

Vascular Endothelial Growth Factor A Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2025 - Product Image

Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Vascular Endothelial Growth Factor Receptor 3 Antagonists - Pipeline Insight, 2025 - Product Image

Vascular Endothelial Growth Factor Receptor 3 Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • 80 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.